Condensed Consolidated Statements of Operations (Unaudited) - USD ($) |
3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2022 |
Jun. 30, 2021 |
Jun. 30, 2022 |
Jun. 30, 2021 |
|
| Operating Expenses | ||||
| Research and development expenses | $ 3,137,292 | $ 1,614,954 | $ 5,181,912 | $ 3,086,401 |
| Acquisition of in-process research and development | 515,630 | 515,630 | ||
| General and administrative expenses | 2,034,456 | 1,329,213 | 3,218,550 | 2,051,073 |
| Operating Loss | (5,171,748) | (3,459,797) | (8,400,462) | (5,653,104) |
| Other Income (Expense) | ||||
| Forgiveness of PPP loan and related accrued interest | 163,771 | 163,771 | ||
| Interest expense | (362) | |||
| Interest income | 7,380 | 1,814 | 8,963 | 6,755 |
| Net Operating Loss Before Income Tax Benefit | (5,164,368) | (3,294,212) | (8,391,499) | (5,482,940) |
| Income Tax Benefit | 137,169 | 226,417 | ||
| Net Loss | $ (5,164,368) | $ (3,157,043) | $ (8,391,499) | $ (5,256,523) |
| Net Loss per Common Share - Basic and Diluted | $ (0.32) | $ (0.20) | $ (0.53) | $ (0.35) |
| Weighted Average Common Shares Used to Compute Net Loss Applicable to Common Shares - Basic and Diluted | 15,940,510 | 15,406,363 | 15,886,116 | 14,997,303 |
| X | ||||||||||
- Definition Forgiveness of payroll protection program loan and related accrued interest. No definition available.
|
| X | ||||||||||
- Definition The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of the cost of borrowed funds accounted for as interest expense. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition. No definition available.
|
| X | ||||||||||
- Definition Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|